Dyslipidemia
Conditions
Brief summary
The purposes of this study are to determine: * The safety of the study medication and any side effects that might be associated with it; * Whether the study medication can help patients with low levels of 'good' cholesterol (HDL-C) and high blood fats or triglycerides (TG); * How much of the study medication should be given to patients; * How the study medication compares to fenofibrate (Lofibra), a drug used for people with low levels of HDL-C and high levels of TG.
Interventions
DRUGPPAR alpha
DRUGplacebo
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Men and women between 18 and 80 years of age * People with abnormal fat levels in the blood (low HDL, high TG)
Exclusion criteria
* People with diabetes * People whose blood pressure is greater than 160/95 mm Hg, on or off blood pressure medicine * People who have had frequent chest pain or unstable angina, a heart attack or a heart procedure, including stent placement, within the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effects on HDL-C and Triglycerides after 12 weeks | — |
| Safety after 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects on LDL-C after 12 weeks | — |
| Effects on biomarkers of atherosclerosis after 12 weeks | — |
| Effects on factors of metabolic syndrome after 12 weeks | — |
Countries
United States
Outcome results
None listed